Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio osservazionale, prospettico, multicentrico e reale sulla EPN in Cina (ReWoPNH)

22 settembre 2026 aggiornato da: AstraZeneca

Uno studio reale, multicentrico, prospettico e osservazionale sull’emoglobinuria parossistica notturna (EPN) in Cina

As a rare disease listed in the First Catalogue of Rare Diseases in China (National Health Commission of the People's Republic of China, 2019), PNH is poorly studied in China subse-quently leading to the inadequate elucidation of disease characteristics and clinical outcomes. Eculizumab was recently approved by NMPA. The availability of Eculizumab in China pro-vides people living with PNH with a new treatment option that can reduce disease symptoms and prevent the dysregulated complement system from causing further damage. A Phase Ⅳ study is necessary to understand the natural history of disease and the clinical outcomes with different medical interventions.

Panoramica dello studio

Stato

Completato

Descrizione dettagliata

Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare and life-threatening acquired disorder of the pluripotent hematopoietic stem cell and therefore can affect erythrocytes, leukocytes, thrombocytes and probably some endothelial cells. These hematopoietic stem cells have acquired a somatic mutation in the phosphatidylinositol glycan class A (PIG-A) This gene is required for the synthesis of the glycosyl phosphatidyl-inositol (GPI) anchor, which is necessary to attach some proteins to the blood cell membrane. Therefore, a lack of two important complement regulatory proteins is observed on the cell surface: 'decay-accelerating factor' (DAF), also called 'CD55' and 'membrane inhibitor of reactive lysis' (MIRL), also called 'CD59' Thus, red blood cells are more vulnerable to the attack by the complement activation product MAC (complement membrane attack complex). This leads to a complement-mediated intravascular hemolysis. The predisposition of venous thrombosis, hemolytic anemia, complete thrombocytopenia, and thrombosis are the three main characteristics of the disease. Its incidence is not really known but estimated at 0.1~0.6/100 000 per-sons/yr, and prevalence is estimated at 1~4 cases/100,000 persons/yr. PNH was listed in the First Catalogue of Rare Diseases in China, and its incidence was previously reported to be 1/100,000 persons/year, peak onset age 20~40 years.

PNH can be classified into 3 different forms: classical PNH, PNH associated with aplastic anemia (PNH-AA), and subclinical PNH, based on clinical features, bone marrow characteristics, and the size of the mutant clone. The traditional treatment of PNH is still aimed at "protecting" the PNH clone, reducing complement attack and destruction, and alleviating hemolysis with symptomatic supportive therapy. In acute hemolytic episodes, could be administered adrenal glucocorticoids, complemented by cell membrane stabilizers, folic acid, and alkaline drugs. In case of PNH-AA syndrome, treatment with androgens and immunosuppressants may be used; anticoagulation and heparin therapy should be given for the occurrence of thrombosis; other symptomatic supportive treatments include transfusion of red blood cells and platelets if necessary as well as antibacterial drugs in case of infection. Bone marrow transplantation is the only curative therapy for PNH presupposes, but patient need to achieve complete remission with chemotherapy first and a suitable donor is needed.

Besides supportive care, global guidance/consensus also recommend C5 complement inhibitor Eculizumab as a treatment method, and its use could significantly improve 5-year survival rate to 95.5%. Eculizumabis a humanized, first-in-class, anti-C5 antibody that binds with high affinity to C5 and blocks the terminal complement-C5a and C5b-9 formation, reducing the chronic uncontrolled complement activation and its consequences. Eculizumab has been approved for PNH by National Medical Products Administration in August, 2022.

Tipo di studio

Osservativo

Iscrizione (Effettivo)

724

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Hangzhou, Cina
        • Research Site
    • Anhui
      • Hefei, Anhui, Cina, 230002
        • Research Site
    • Beijing Municipality
      • Beijing, Beijing Municipality, Cina, 100000
        • Research Site
      • Beijing, Beijing Municipality, Cina, 100044
        • Research Site
    • Guangdong
      • Guangzhou, Guangdong, Cina, 510080
        • Research Site
      • Guangzhou, Guangdong, Cina, 510180
        • Research Site
      • Guangzhou, Guangdong, Cina, 510515
        • Research Site
    • Guangxi
      • Nanning, Guangxi, Cina, 530021
        • Research Site
    • Guizhou
      • Guiyang, Guizhou, Cina, 550004
        • Research Site
    • Hebei
      • Shijiazhuang, Hebei, Cina, 050000
        • Research Site
    • Heilongjiang
      • Harbin, Heilongjiang, Cina, 150001
        • Research Site
    • Henan
      • Zhengzhou, Henan, Cina, 450003
        • Research Site
      • Zhengzhou, Henan, Cina, 450052
        • Research Site
      • Zhengzhou, Henan, Cina, 463599
        • Research Site
    • Hubei
      • Wuhan, Hubei, Cina, 430030
        • Research Site
      • Wuhan, Hubei, Cina, 430000
        • Research Site
    • Hunan
      • Changsha, Hunan, Cina, 410008
        • Research Site
      • Changsha, Hunan, Cina, 410005
        • Research Site
    • Jiangsu
      • Nanjing, Jiangsu, Cina, 210029
        • Research Site
      • Nantong, Jiangsu, Cina, 226001
        • Research Site
      • Xuzhou, Jiangsu, Cina, 221002
        • Research Site
    • Jiangxi
      • Nanchang, Jiangxi, Cina, 330006
        • Research Site
      • Nanchang, Jiangxi, Cina, 330008
        • Research Site
    • Jilin
      • Changchun, Jilin, Cina, 130021
        • Research Site
    • Liaoning
      • Shenyang, Liaoning, Cina, 110001
        • Research Site
    • Shandong
      • Jinan, Shandong, Cina, 250000
        • Research Site
      • Qingdao, Shandong, Cina, 266000
        • Research Site
      • Zibo, Shandong, Cina, 255090
        • Research Site
    • Shangdong
      • Linyi, Shangdong, Cina, 276034
        • Research Site
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Cina, 200040
        • Research Site
      • Shanghai, Shanghai Municipality, Cina, 200336
        • Research Site
    • Shanxi
      • Taiyuan, Shanxi, Cina, 030000
        • Research Site
      • Xi’an, Shanxi, Cina, 710061
        • Research Site
      • Xi’an, Shanxi, Cina, 710068
        • Research Site
    • Sichuan
      • Chengdu, Sichuan, Cina, 610041
        • Research Site
      • Chengdu, Sichuan, Cina, 610072
        • Research Site
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Cina, 300020
        • Research Site
      • Tianjin, Tianjin Municipality, Cina, 300052
        • Research Site
      • Tianjin, Tianjin Municipality, Cina, 300190
        • Research Site
    • Yunnan
      • Kunming, Yunnan, Cina, 650034
        • Research Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Study Population:

Number of patients (estimate): 1000; Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

Descrizione

Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Hemolysis:Concentration of LDH changes at each visit from base-line, of all patients
Lasso di tempo: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with thrombosis within follow-up
Lasso di tempo: 12 months

To characterize the progression of PNH

12 months
average number of units of packed RBCs transfused per month, of all patients
Lasso di tempo: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with renal failure within follow-up
Lasso di tempo: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with pulmonary hypertension within follow-up
Lasso di tempo: 12 months

To characterize the progression of PNH

12 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number and percentage of patients with each symptom of interest within follow-up
Lasso di tempo: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Demographics at baseline of all patients
Lasso di tempo: baseline

To describe clinical characteristics of patients with PNH in China

baseline
Number and percentage of patients receiving each type of treatment method at baseline and each visit within follow up, including glucocorticoid, red blood cell transfusion, other supportive treatment, bone marrow transplant, eculizumab, of all patients
Lasso di tempo: 12 months

To describe the treatment pattern of PNH in China

12 months
All serious adverse events (SAEs)of PNH among eculizumab-treated patients
Lasso di tempo: 12 months

To describe the safety of Eculizumab treatment via Serious Adverse Events

12 months
Standard descriptive statistics of pregnancy status
Lasso di tempo: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of lactation status
Lasso di tempo: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of PNH classification
Lasso di tempo: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of flow cytometry results
Lasso di tempo: 12 months

To describe clinical characteristics of patients with PNH in China

12 months

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Concentration of LDH changes at each visit from base-line of PNH among eculizumab-treated patients
Lasso di tempo: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with thrombosis within follow up among eculizumab-treated patients
Lasso di tempo: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
average number of units of packed RBCs transfused per month within 12 months v
Lasso di tempo: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with renal failure within follow up among eculizumab-treated patients
Lasso di tempo: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with pulmonary hypertension (PH) within follow up among eculizumab-treated patients
Lasso di tempo: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Collegamenti utili

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

10 novembre 2023

Completamento primario (Effettivo)

3 dicembre 2025

Completamento dello studio (Effettivo)

3 dicembre 2025

Date di iscrizione allo studio

Primo inviato

30 ottobre 2023

Primo inviato che soddisfa i criteri di controllo qualità

23 novembre 2023

Primo Inserito (Effettivo)

4 dicembre 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

24 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

22 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • D7414R00001

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Periodo di condivisione IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Criteri di accesso alla condivisione IPD

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi